Content about Economy of New York City

May 9, 2013
Costco comps increase 4% in April

Costco sales grew 7% in April over April 2012, the club retailer said.

ISSAQUAH, Wash. — Costco Wholesale Corp.'s sales grew 7% in April over April 2012, the club retailer said Thursday.

Costco reported sales of $7.98 billion for the four weeks that ended Sunday, compared with $7.48 billion during the same period last year. Sales for the 35-week period that ended Sunday were $69 billion, 9% higher than the $63.59 billion recorded last year.

Sales in the United States at continuously open stores since last April increased by 4%, while same-store sales for the 35 weeks that ended Sunday increased 6%.

April 8, 2013
Safeway hoping to raise as much as $220 million through Blackhawk IPO

Blackhawk Network Holdings announced its intent to open its initial public offering of 10 million shares at an estimated offering price of $20 to $22 per share.

PLEASANTON, Calif. — Blackhawk Network Holdings on Monday announced its intent to open its initial public offering of 10 million shares at an estimated offering price of $20 to $22 per share. The IPO will consist solely of shares to be offered by existing stockholders, including Safeway, and could raise as much as $220 million. 

February 11, 2013
Mylan appoints two new board members

Mylan has appointed its president and a former partner at Goldman Sachs to its board of directors, the generic drug maker said.

PITTSBURGH — Mylan has appointed its president and a former Goldman Sachs & Co. partner to its board, the generic drug maker said Monday.

Mylan announced the appointment of president Rajiv Malik and former Goldman Sachs partner Melina Higgins to its board.

January 4, 2013
Bloomberg: B&L on sales block for as much as $10 billion

According to a Bloomberg report, Abbott Laboratories, Johnson & Johnson and Sanofi are all potential suitors for Bausch & Lomb's eye care business in a deal that could be valued as high as $10 billion.

NEW YORK — According to a Bloomberg report published Friday morning, Abbott Laboratories, Johnson & Johnson and Sanofi are all potential suitors for Bausch & Lomb's eye care business in a deal that could be valued as high as $10 billion. 

B&L is being shopped by private equity firm Warburg Pincus, which is working with Goldman Sachs Group, Bloomberg reported, and both Abbott and Sanofi have contracted financial advisors as well. 

Other companies who have been invited to bid include Merck and Pfizer. 

December 21, 2012
Watson to present at Goldman Sachs, J.P. Morgan healthcare conferences

Watson Pharmaceuticals will present at two conferences sponsored by financial banks, the company said.

PARSIPPANY, N.J. — Watson Pharmaceuticals will present at two conferences sponsored by financial banks, the company said.

Watson said that president and CEO Paul Bisaro would provide an overview and update of the company's business at the 2013 Goldman Sachs "Healthcare CEOs Unscripted: A View from the Top" conference, scheduled for Jan. 3, 2013, at the Goldman Sachs Conference Center in New York.

Six days later, on Jan. 9, Bisaro will present at the annual J.P. Morgan Healthcare Conference, at the Westin St. Francis Hotel in San Francisco.

December 19, 2012
Citi analyst: Flu activity up year over year in early December

Predictions of a more active flu season are coming true as temperature differences have helped drive flu activity, a Citibank financial analyst wrote.

NEW YORK — Predictions of a more active flu season are coming true as temperature differences have helped drive flu activity, a Citibank financial analyst wrote.

In a letter to investors, Citi Research analyst Deborah Weinswig wrote that influenza virus activity in the week ended Dec. 8 increased year over year for the ninth consecutive time this season and increased significantly compared with last week — up 28.3% compared with last week's 20.7%.

September 4, 2012
Deep discounter Fred's to begin accepting American Express

American Express and Fred's on Friday announced the launch of a special three-month American Express Cardmember offer beginning in September to celebrate the recent card acceptance agreement between the two companies.

NEW YORK 

June 8, 2012
Kraft Foods shifts stock listing to NASDAQ

Kraft Foods announced that it has shifted its stock listing from the New York Stock Exchange to the NASDAQ global select market.

NORTHFIELD, Ill. — Kraft Foods announced that it has shifted its stock listing from the New York Stock Exchange to the NASDAQ global select market.

The company said its decision to shift its listing — which still will trade under the ticker symbol KFT — will yield greater cost efficiencies, while providing visibility advantages for the company's iconic brands. Kraft Foods begin trading on NASDAQ on June 26.

May 31, 2012
Teva makes the switch from NASDAQ to NYSE

Teva Pharmaceutical Industries has transferred its stock listing from NASDAQ to the New York Stock Exchange, the drug maker said Wednesday.

NEW YORK — Teva Pharmaceutical Industries has transferred its stock listing from NASDAQ to the New York Stock Exchange, the drug maker said Wednesday.

The company began trading on the NYSE under the ticker symbol "TEVA." On hand Wednesday to ring the Opening Bell and celebrate the company's first day of trading on NYSE were Teva's new president and CEO Jeremy Levin, as well as board chairman Phillip Frost, CFO Eyal Desheh, Teva Americas CEO William Marth and employees from Teva's businesses around the world.

July 5, 2011
ProPhase faces NASDAQ delisting

ProPhase Labs on Tuesday announced that it received a letter from the NASDAQ Stock Market indicating that the company no longer is in compliance with NASDAQ listing rules because the closing bid price per share of its common stock has dropped below $1 per share for 30 consecutive trading days.

DOYLESTOWN, Pa. — ProPhase Labs on Tuesday announced that it received a letter from the NASDAQ Stock Market indicating that the company no longer is in compliance with NASDAQ listing rules because the closing bid price per share of its common stock has dropped below $1 per share for 30 consecutive trading days.

ProPhase will have until Dec. 27 to push its stock price above $1 for a minimum of 10 consecutive trading days to regain compliance or risk being delisted.